$IKT

Inhibikase Therapeutics, Inc. (IKT) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. EX-4.1 2 d78217dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 INHIBIKASE THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2026 Inhibikase Therapeutics, Inc. , a Delaware corporation (th

Biotech stocks hit 52-week highs on July 24, 2026, including Inhibikase Therapeutics (IKT) at $2.53 after FDA orphan drug designation for IKT-001 and Phase 3 IMPROVE-PAH progress. Jazz Pharmaceuticals (JAZZ) reached $256.75, with Q1 2026 revenue up 19% to $1.1B. Halozyme (HALO) hit $82.99, Q1 revenue $376M (+42%). Corcept (CORT) rose to $97.63, Q1 revenue $164M. Liquidia (LQDA) reached $91.10 on YUTREPIA revenue and net income.

Inhibikase Therapeutics (IKT) said it sold 25 million shares via an at-the-market facility to RA Capital Management, raising $50 million in gross proceeds. The company plans to use the funds, plus reserves, to support operations through topline data from Part B of its Phase 3 IMPROVE-PAH study for IKT-001, pending warrant exercise. Shares rose about 5% to $2.06.

Biotech and healthcare stocks hit 52-week highs on July 14, 2026. The Oncology Institute (TOI) reached $6.66 after repaying an $86 million senior convertible note and projecting 2026 revenue of $630 million to $650 million. Inhibikase (IKT) rose above $2.36 after a $50 million ATM sale. Alto Neuroscience (ANRO) hit $28.85 after a $100 million direct offering. Elevance (ELV) touched $434.38, guiding 2026 adjusted diluted EPS of at least $26.75. Privia (PRVA) hit $28.30, estimating 2026 GAAP reven

Inhibikase Therapeutics (Nasdaq: IKT) said it granted non-qualified stock options to seven newly hired non-executive employees under its 2026 Inducement Equity Plan. Up to 981,243 shares were covered; options priced at $2.03 per share (June 30, 2026 close) with a 10-year term and vesting starting after one year.

Inhibikase Therapeutics, Inc. (IKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001750149 --12-31 0001750149 2026-06-26 2026-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J

Inhibikase Therapeutics reported its first-quarter 2026 financial results, showing a net loss of $16.4 million but maintaining a strong cash position of $170.4 million. The company announced significant progress for its IKT-001 drug in pulmonary arterial hypertension (PAH), including the enrollment of the first patient in the global Phase 3 IMPROVE-PAH trial, which has regulatory approvals in 16 countries. Inhibikase also submitted an Orphan Drug Designation application for IKT-001 to the U.S. FDA, highlighting advancements in its clinical development.

Inhibikase Therapeutics Inc has reported its earnings summary for the quarter ended December 31. The report is a brief overview of the company's financial results for that period.

Inhibikase Therapeutics (NASDAQ:IKT) saw a significant increase in short interest during December, rising by 29.0% to 5,345,574 shares as of December 15th. This represents about 7.7% of the company's stock, resulting in a days-to-cover ratio of 13.8 days based on average daily volume. Analyst ratings are mixed but lean positive, with a MarketBeat consensus of "Buy," including recent upgrades to "Strong Buy" from Cantor Fitzgerald and Lifesci Capital.

WILMINGTON, Del., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Inhibikase Therapeutics, Inc. ( NASDAQ:IKT ) ( "Inhibikase" or "Company" ) , a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension ( "PAH" ) , today announced the pricing of ...